Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10 - Arla Food’s strict quality checks and emphasis on regulatory compliance earn it a leading position in the whey ingredients and infant formula market - ArlaFoodsIngredients.com / Frost.com
Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10

 

PRZOOM - /newswire/ - Santa Clara, CA, United States, 2018/10/15 - Arla Food’s strict quality checks and emphasis on regulatory compliance earn it a leading position in the whey ingredients and infant formula market - ArlaFoodsIngredients.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the global infant nutrition market, Frost & Arla-Foods-Ingredients-Award-Logo.jpgSullivan recognizes Arla Foods Ingredients (AFI) with the 2018 Global Product Leadership Award for developing an innovative infant formula ingredient, Lacprodan® OPN-10. Lacprodan® OPN-10 is rich in osteopontin, a protein that standard infant formulas have significantly lower content compared to human breast milk.

"After identifying that human milk has up to 20 times more osteopontin than conventional infant formula, AFI worked diligently to bring the osteopontin content in its offerings on par with human milk concentrations. Consequently, it pioneered the commercial use of osteopontin in infant formula with its product Lacprodan® OPN-10." said Arun Ramesh, Industry Analyst at Frost & Sullivan.

AFI's strong emphasis on research and development and its global footprint allow the company to anticipate and meet customer needs through value-added products. Arla AMBA, the mother company of AFI, has more than 10,000 farmers and some of the largest dairies in the world, which gives AFI a complete control over the value chain. Its farmers follow an intensive quality control program that includes numerous audits and compliance with rules regarding the treatment of cows, filtering of contaminants, and extraction and delivery of high-quality milk.

AFI's focus on sustainability, operational excellence, and dedication to meeting and exceeding regulatory requirements has positioned it for continued and accelerated growth in the infant formula market. Furthermore, AFI’s powerful partnerships with leading universities, non-governmental organizations, and other thought leaders endow it with a comprehensive knowledge base that serves as a foundation for innovation.

"AFI's ambitious quality strategy elevates the company to a leader status in the market," noted Ramesh. "Its commitment to technology innovation and strategic collaborations have given it a significant competitive advantage, and the company expects to make the most of it by expanding to numerous new markets in the future."

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Arla Foods Ingredients (AFI)

Arla Foods Ingredients (arla.com | arlafoodsingredients.com) is a global leader in value-added whey solutions. We discover and deliver ingredients derived from whey, supporting the food industry with the development and efficient processing of more natural, functional and nutritious foods. We serve global markets within early life nutrition, medical nutrition, sport nutrition, health foods and other foods and beverage products.

Five reasons to choose us:

• We have R&D in our DNA;
• We offer superior quality;
• We are your trusted business partner;
• We support sustainability;
• We ensure security of supply.

Arla Foods Ingredients is a 100% owned subsidiary of Arla Foods. Our head office is in Denmark.

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Arla Osteopontin | Frost & Sullivan
Contact: Claudia Toscano - Frost.com 
210-477-8417 claudia.toscano[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  Huntington Study Group Ltd

Visit  BizJobs.com







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today